

Pergamon Tetrahedron Letters 43 (2002) 9691–9693

## **Synthesis of chiral α-amino acids**

Tushar K. Chakraborty\* and Animesh Ghosh

*Indian Institute of Chemical Technology*, *Hyderabad* 500 007, *India* Received 15 July 2002; revised 17 October 2002; accepted 18 October 2002

Abstract—A novel method for the synthesis of chiral  $\alpha$ -amino acids has been developed where the acid functionality was constructed by oxidizing a hydroxymethyl group introduced by Evans' method in the  $\alpha$ -position of an appropriate acid substrate and the amino part came from the amide of the original carboxyl group following a modified Hofmann rearrangement reaction. © 2002 Published by Elsevier Science Ltd.

While there are many forms of amino acids, all of the important amino acids found in living organisms are  $\alpha$ -amino acids. In addition to the 20 natural ones, there are many other  $\alpha$ -amino acids found in various natural products.<sup>1</sup> Total syntheses of these natural products depend largely on the efficient construction of these unusual  $\alpha$ -amino acids. Although a large number of methods are available for the synthesis of  $\alpha$ -amino acids,<sup>2</sup> there is always scope for the development of new and more efficient methods that could be useful for the synthesis of many of these unusual  $\alpha$ -amino acids, en route to the total synthesis of their parent natural products. While our earlier method for the diastereoselective Strecker synthesis of  $\alpha$ -amino acids using  $\alpha$ phenylglycinol as chiral auxiliary worked well for  $\alpha$ -aryl substrates, the selectivities were not good with  $\alpha$ -alkylsubstituted compounds.<sup>3</sup> In this paper, we describe a new method for the stereoselective synthesis of  $\alpha$ -amino acids that works equally well with both alkyl and aryl-substituted compounds and can be applied to prepare both D- and L-isomers.

Scheme 1 outlines the steps involved in this novel method of synthesizing  $\alpha$ -amino acids. The salient features of this route are: (a) the carboxyl group of the final amino acids was obtained by oxidation of an -hydroxymethyl group that was introduced in the  $\alpha$ -position of the corresponding carboxylic substrate by Evans' method; $4$  (b) the original carboxyl group was converted to an amide that was transformed into the amino group by a modified Hofmann rearrangement reaction.<sup>5</sup>

The synthesis started with the chiral oxazolidinone **1**. Treatment of 1 with  $TiCl<sub>4</sub>$  in the presence of diisopropylethylamine (DIPEA) in  $CH<sub>2</sub>Cl<sub>2</sub>$  provided the Tienolate that was reacted with benzyloxymethyl chloride following Evans' method<sup>4</sup> to furnish the Bn-protected -hydroxymethyl-substituted intermediate **2**<sup>6</sup> with excellent diastereoselectivity  $(>98\%)$ .<sup>7</sup> Removal of the chiral auxiliary<sup>8</sup> using LiOH–H<sub>2</sub>O<sub>2</sub> led to the formation of an acid **3**<sup>6</sup> that was transformed into its amide **4** in the next step by the mixed anhydride method.<sup>9</sup> Treatment of 3 with ethyl chloroformate in the presence of  $Et<sub>3</sub>N$ gave an intermediate mixed anhydride which was reacted in situ with NH4OH to provide the amide **4**. With the amide in hand, the stage was now set to carry out the crucial Hofmann rearrangement reaction.<sup>5</sup> Accordingly, the amide **4** was treated with [bis(trifluoroacetoxy)iodo]benzene $[PhI(CF_3COO)_2]$  in  $CH_3CN H<sub>2</sub>O$  (1:1) to provide the corresponding amine that was treated in situ with  $Boc<sub>2</sub>O$  and  $Et<sub>3</sub>N$  to furnish the Boc-protected intermediate **5**. The Bn-protection was removed by hydrogenation over  $Pd(OH)_{2}-C$  and the resulting primary hydroxyl of **6** was oxidized to the acid using  $RuCl<sub>3</sub>-NaIO<sub>4</sub>$  furnishing the *N*-Boc protected -amino acids **7** in excellent overall yields. Finally, treatment with dilute HCl removed the Boc-protection to give, after evaporation to dryness under reduced pressure, the desired D-amino acid **8** as its HCl salt.6

Compound **7a** on treatment with  $CH_2N_2$  in ether gave Boc-D-Ala-OMe that showed rotation,  $[\alpha]_D^{22} = +45.2$  (*c* 1.75, MeOH), matching with that of commercially available Boc-D-Ala-OMe.<sup>10</sup>

In conclusion, an excellent method for the synthesis of -amino acids has been developed that will find useful applications in preparing many unusual  $\alpha$ -amino acids

*Keywords*: α-amino acids: Hofmann rearrangement: oxazolidinone: Evans' reaction.

<sup>\*</sup> Corresponding author. Fax: +91-40-7160387, 7160757; e-mail: [chakraborty@iict.ap.nic.in](mailto:chakraborty@iict.ap.nic.in)



**Scheme 1.** Synthesis of  $\alpha$ -amino acids. *Reagents and conditions*: (i) TiCl<sub>4</sub> (1.05 equiv.), DIPEA (1.1 equiv.), CH<sub>2</sub>Cl<sub>2</sub>, 0°C, 1 h, followed by BnOCH2Cl (2.0 equiv.), 0°C, 6 h (92% for **1a**, 87% for **1b**, 89% for **1c**, 80% for **1d** and 85% for **1e**). (ii) LiOH (2.0 equiv.), aq. H2O2 (30%, 6.0 equiv.), THF–H2O (3:1, 0.05 M conc.), 0°C to rt, 5 h (87% for **2a**, 90% for **2b**, 91% for **2c**, 88% for **2d** and 86% for **2e**). (iii) Et<sub>3</sub>N (1.1 equiv.), ClCO<sub>2</sub>Et (1.0 equiv.), THF, −20°C, 0.5 h, then NH<sub>4</sub>OH (5.0 equiv.), 0°C, 1.5 h (90% for **3a**, 95% for **3b**, 92% for **3c**, 90% for **3d** and 93% for **3e**). (iv) PhI(CF<sub>3</sub>CO<sub>2</sub>), (1.5 equiv.), CH<sub>3</sub>CN–H<sub>2</sub>O (1:1), rt, 2.5 h, then Boc<sub>2</sub>O (2.0 equiv.), Et<sub>3</sub>N (4.0 equiv.), 0°C, 1 h (72% for **4a**, 68% for **4b**, 73% for **4c**, 70% for **4d** and 66% for **4e**). (v) Pd(OH)<sub>2</sub>–C (cat.), H<sub>2</sub>, MeOH, rt, 1 h (95% for **5a**, 96% for **5b**, 93% for **5c**, 97% for **5d** and 90% for **5e**). (vi) RuCl<sub>3</sub>:3H<sub>2</sub>O (0.01 equiv.), NaIO<sub>4</sub> (3.0 equiv.), CCl4–CH3CN–H2O (1:1:1.5), 0°C to rt, 1 h (75% for **6a**, 77% for **6b**, 68% for **6c**, 67% for **6d** and 62% for **6e**). (vii) dil. HCl, 0°C to rt, 1 h (95% for **7a**).

in either enantiomeric form starting from an appropriate chiral oxazolidinone. While L-phenylalanine-based oxazolidone **1** gives D-amino acids, as shown in this paper, its D-isomer could be similarly used to prepare the corresponding L-amino acids. Further work is in progress.

## **Acknowledgements**

The authors wish to thank CSIR, New Delhi for research fellowship (A.G.).

## **References**

- 1. (a) Burja, A. M.; Banaigs, B.; Abou-Mansour, E.; Burgess, J. G.; Wright, P. C. *Tetrahedron* **2001**, <sup>57</sup>, 9347–9377. It is not possible to list here all the references on the natural products containing unusual amino acids. However, a search in http://www.heterocycles.jp/hetero/ frame–db.html will provide a quick access to many of these molecules, their structures and references.
- 2. For some recent works on the synthesis of  $\alpha$ -amino acids, see: (a) Xiong, C.; Wang, W.; Hruby, V. J. *J*. *Org*. *Chem*. **2002**, 67, 3514–3517; (b) Bøgevig, A.; Juhl, K.; Kumaragurubaran, N.; Zhuang, W.; Karl Anker Jørgensen, K. A. *Angew*. *Chem*., *Int*. *Ed*. **2002**, 41, 1790– 1793; (c) Cordova, A.; Notz, W.; Zhong, G.; Betancort, J. M.; Barbas, C. F., III *J*. *Am*. *Chem*. *Soc*. **2002**, 124, 1842–1843; (d) Hang, J.; Tian, S.-K.; Tang, L.; Deng, L. *J*. *Am*. *Chem*. *Soc*. **2001**, 123, 12696–12697; (e) Anakabe,

E.; Vicario, J. L.; Bad´ıa, D.; Carrillo, L.; Yoldi, V. *Eur*. *J*. *Org*. *Chem*. **2001**, 4343–4352; (f) Belokon, Y. N.; Kochetkov, K. A.; Churkina, T. D.; Ikonnikov, N. S.; Larionov, O. V.; Harutyunyan, S. R.; Vyskocil, S.; North, M.; Kagan, H. B. *Angew*. *Chem*., *Int*. *Ed*. **2001**, 40, 1948–1951; (g) Huang, T.-S.; Li, C.-J. *Org*. *Lett*. **2001**, 3, 2037–2040; (h) Boesten, W. H. J.; Seerden, J.-P. G.; de Lange, B.; Dielemans, H. J. A.; Elsenberg, H. L. M.; Kaptein, B.; Moody, H. M.; Kellogg, R. M.; Broxterman, Q. B. *Org*. *Lett*. **2001**, 3, 1121–1124. (i) Yet, L. *Angew*. *Chem*., *Int*. *Ed*. **2001**, 40, 875–877; (j) Guillena, G.; Najera, C. *Tetrahedron*: *Asymmetry* **2001**, 12, 181– 184; (k) Davis, F. A.; Lee, S.; Zhang, H.; Fanelli, D. L. *J*. *Org*. *Chem*. **2000**, 65, 8704–8708; (l) Oertel, K.; Zech, G.; Kunz, H. *Angew*. *Chem*., *Int*. *Ed*. **2000**, 39, 1431– 1433; (m) Sigman, M. S.; Vachal, P.; Jacobsen, E. N. *Angew*. *Chem*., *Int*. *Ed*. **2000**, 39, 1279–1281; (n) Ooi, T.; Kameda, M.; Maruoka, K. *J*. *Am*. *Chem*. *Soc*. **1999**, 121, 6519–6520; (o) Myers, A. G.; Gleason, J. L. *Org*. *Synth*. **1999**, 76, 57–76; (p) Beller, M.; Eckert, M.; Geissler, H.; Napierski, B.; Rebenstock, H.-P.; Holla, E. W. *Chem*. *Eur*. *J*. **1998**, <sup>4</sup>, 935–941.

- 3. (a) Chakraborty, T. K.; Hussain, K. A.; Reddy, G. V. *Tetrahedron* **1995**, 51, 9179–9190; (b) Chakraborty, T. K.; Reddy, G. V.; Hussain, K. A. *Tetrahedron Lett*. **1991**, 32, 7597–7600.
- 4. Evans, D. A.; Urpi, F.; Somers, T. C.; Clark, J. S.; Bilodeau, M. T. *J*. *Am*. *Chem*. *Soc*. **1990**, 112, 8215–8216.
- 5. (a) Yu, C.; Jiang, Y.; Liu, B.; Hu, L. *Tetrahedron Lett*. **2001**, <sup>42</sup>, 1449–1452; (b) Huang, X.; Seid, M.; Keillor, J. W. *J*. *Org*. *Chem*. **1997**, 62, 7495–7496; (c) Zhang, L.; Kauffman, G. S.; Pesti, J. A.; Yin, J. *J*. *Org*. *Chem*. **1997**, 62, 6918–6920; (d) Waki, M.; Kitajima, Y.; Izumiya, N. *Synthesis* **1981**, 266–268.
- 6. All new compounds were characterized by IR, NMR and mass spectroscopic studies.
- 7. The other isomer could not be detected by  $H$  NMR analysis of the product.
- 8. Evans, D. A.; Britton, T. C.; Ellman, J. A. *Tetrahedron Lett*. **1987**, 28, 6141–6144.
- 9. Kawamoto, I.; Endo, R.; Ishikawa, K.; Kojima, K.; Miyauchi, M.; Nakayama, E. *Synlett* **1995**, 575–577.
- 10. Selected physical data for **7a** methyl ester: <sup>1</sup> H NMR (CDCl<sub>3</sub>, 200 MHz): δ 4.95 (s, 1H, BocN*H*), 4.28 (m, 1H, C $\alpha$ H), 3.75 (s, 3H, CO<sub>2</sub>Me), 1.40 (s, 9H, Boc), 1.36 (d,  $J=6.9$  Hz, 3H, Me).  $[\alpha]_D^{22} = +45.2$  (*c* 1.75, MeOH), matching with that of an authentic sample prepared from D-Ala. Selected physical data for 7**b** methyl ester: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz):  $\delta$  7.30 (m, 5H, Ph), 5.50 (d,  $J=6.6$  Hz, 1H, BocN*H*), 5.25 (d,  $J=6.6$  Hz, 1H, C $\alpha$ *H*), 3.70 (s, 3H, CO<sub>2</sub>Me), 1.35 (s, 9H, Boc).  $[\alpha]_D^{22} = -138.6$  (*c* 1.6,  $CHCl<sub>3</sub>$ ), matching with that of an authentic sample prepared from D-Phg. MS (LSIMS):  $m/z$  210 (M<sup>+</sup>+Na– PhH), 166 ( $M^+ + H - C_5H_8O_2$ ). Selected physical data for **7c** methyl ester: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz):  $\delta$  4.90 (d, *J*=6.97 Hz, 1H, BocN*H*), 4.25 (m, 1H, C $\alpha$ *H*), 3.70 (s,

3H, CO<sub>2</sub>Me), 1.20–1.80 (m, 14H, CH<sub>2</sub>), 1.40 (s, 9H, Boc), 0.90 (t,  $J=5.6$  Hz, 3H, Me). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 50) MHz):  $\delta$  173.50, 155.50, 79.50, 53.41, 52.09, 32.70, 31.76, 29.28, 29.11, 28.26, 25.21, 22.58, 14.02.  $[\alpha]_D^{22} = -13.8$  (*c* 1.85, CHCl<sub>3</sub>). MS (LSIMS):  $m/z$  302 (M<sup>+</sup>+H), 202 (M<sup>+</sup>+ H−C<sub>5</sub>H<sub>8</sub>O<sub>2</sub>). Selected physical data for **7d** methyl ester: H NMR (CDCl<sub>3</sub>, 200 MHz):  $\delta$  4.95 (d, *J* = 7.90 Hz, 1H, BocN*H*), 4.25 (m, 1H, C $\alpha$ *H*), 3.75 (s, 3H, CO<sub>2</sub>Me), 1.20–1.85 (m, 39H, C*H*<sup>2</sup> and Boc), 0.95 (t, *J*=5.58 Hz, 3H, Me). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 50 MHz):  $\delta$  173.50, 155.33, 79.73, 53.41, 52.10, 32.71, 31.86, 29.51, 29.45, 29.33,  $29.26, 29.14, 28.27, 27.96, 25.23, 22.63, 14.06. [\alpha]_D^{22} =$ −11.51 (*c* 2.5, CHCl3). MS (LSIMS): *m*/*z* 355 (M<sup>+</sup> +H− CO<sub>2</sub>CH<sub>3</sub>). Selected physical data for 7e methyl ester: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz):  $\delta$  4.95 (d, J=6.54 Hz, 1H, BocN*H*), 4.21 (m, 1H, C $\alpha$ *H*), 3.70 (s, 3H, CO<sub>2</sub>Me), 3.32  $(t, J=7.27 \text{ Hz}, 2H, CH_2Br), 1.10-1.90 \text{ (m, 14H, } CH_2),$ 1.40 (s, 9H, Boc). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 50 MHz):  $\delta$  173.44, 155.30, 79.74, 53.35, 52.12, 33.93, 32.72, 32.67, 29.19, 29.04, 28.62, 28.25, 28.05, 25.17.  $[\alpha]_D^{22} = -10.42$  (*c* 2.0, CHCl<sub>3</sub>). MS (LSIMS): *m*/*z* 279, 281 (M<sup>+</sup>−C<sub>5</sub>H<sub>8</sub>O<sub>2</sub>).